Impact of Hydroxyurea Starting Dose on Pain Outcomes in Patients with Sickle Cell Disease

References

• Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease – life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–44. doi:10.1056/NEJM199406093302303.
   PubMed Web of Science ®Google Scholar
• Keikhaei B, Yousefi H, Bahadoram M. Hydroxyurea: clinical and hematological effects in patients with sickle cell anemia. Glob J Health Sci. 2015;8(3):252–6. doi:10.5539/gjhs.v8n3p252.
   PubMedGoogle Scholar
• Fitzhugh CD, Hsieh MM, Allen D, Coles WA, Seamon C, Ring M, Zhao X, Minniti CP, Rodgers GP, Schechter AN, et al. Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia. PLoS ONE. 2015;10(11):e0141706. doi:10.1371/journal.pone.0141706.
   PubMed Web of Science ®Google Scholar
• Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039–45. doi:10.1182/blood-2003-07-2475.
   PubMed Web of Science ®Google Scholar
• Lima CSP, Arruda VR, Costa FF, Saad STO. Minimal doses of hydroxyurea for sickle cell disease. Braz J Med Biol Res. 1997;30(8):933–40. doi:10.1590/s0100-879x1997000800004.
   PubMed Web of Science ®Google Scholar
• Sharef SW, Al-Hajri M, Beshlawi I, Al-Shahrabally A, Elshinawy M, Zachariah M, Mevada ST, Bashir W, Rawas A, Taqi A, et al. Optimizing hydroxyurea use in children with sickle cell disease: low dose regimen is effective. Eur J Haematol. 2013;90(6):519–24. doi:10.1111/ejh.12103.
   PubMed Web of Science ®Google Scholar
• Antunes FD, Propheta VGS, Vasconcelos HA, Cipolotti R. Neuropathic pain in patients with sickle cell disease: a cross-sectional study assessing teens and young adults. Ann Hematol. 2017; 96(7):1121–5. doi:10.1007/s00277-017-2984-z.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI. Adherence to hydroxyurea, health-related quality of life domains, and patients’ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health Qual Life Outcomes. 2017;15(1):136. doi:10.1186/s12955-017-0713-x.
   PubMed Web of Science ®Google Scholar
• Bekele E, Thornburg CD, Brandow AM, Sharma M, Smaldone AM, Jin Z, Green NS. Do difficulties in swallowing medication impede the use of hydroxyurea in children? Pediatr Blood Cancer. 2014;61(9):1536–9. doi:10.1002/pbc.25073.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–22. doi:10.1056/NEJM199505183322001.
   PubMed Web of Science ®Google Scholar
• DeBaun MR, Field JJ. Limitations of clinical trials in sickle cell disease: a case study of the multi-center study of hydroxyurea (MSH) trial and the stroke prevention (STOP) trial. Hematology. 2007;2007(1):482–8. doi:10.1182/asheducation-2007.1.482.
   Google Scholar
• Dong M, McGann PT, Mizuno T, Ware RE, Vinks AA. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Br J Clin Pharmacol. 2016;81(4):742–52. doi:10.1111/bcp.12851.
   PubMed Web of Science ®Google Scholar
• Estepp JH, Smeltzer MP, Kang G, Li C, Wang WC, Abrams C, Aygun B, Ware RE, Nottage K, Hankins JS, et al. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Am J Hematol. 2017;92(12):1333–9. doi:10.1002/ajh.24906.
   PubMed Web of Science ®Google Scholar
• Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS. Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug Saf. 2018;27(5):479–86. doi:10.1002/pds.4291.
   PubMed Web of Science ®Google Scholar
• Pule GD, Mowla S, Novitzky N, Wiysonge CS, Wonkam A. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Rev Hematol. 2015; 8(5):669–79. doi:10.1586/17474086.2015.1078235.
   PubMed Web of Science ®Google Scholar
• Quarmyne M-O, Dong W, Theodore R, Anand S, Barry V, Adisa O, Buchanan ID, Bost J, Brown RC, Joiner CH, et al. Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: a large retrospective, population-based cohort. Am J Hematol. 2017;92(1):77–81. doi:10.1002/ajh.24587.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ, Multicenter Study of Hydroxyurea. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood. 1997;89(3):1078–88. doi:10.1182/blood.V89.3.1078.
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148(12):939–55. doi:10.7326/0003-4819-148-12-200806170-00221.
   PubMed Web of Science ®Google Scholar
• Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, Smeltzer MP, Kimble AC, Aygun B, Wu S, Howard T, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood. 2011;118(18):4985–91. doi:10.1182/blood-2011-07-364190.
   PubMed Web of Science ®Google Scholar
• Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010; 156(3):415–9. doi:10.1016/j.jpeds.2009.09.044.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, et al. Management of sickle cell disease. JAMA. 2014;312(10):1033–48. doi:10.1001/jama.2014.10517.
   PubMed Web of Science ®Google Scholar
• Ballas SK, Bauserman RL, McCarthy WF, Castro OL, Smith WR, Waclawiw MA. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage. 2010;40(6):870–82. doi:10.1016/j.jpainsymman.2010.03.020.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2021, June 4. “Analyzing Opioid Prescription Data and Oral Morphine Milligram Equivalents (MME).” Opioids, Centers for Disease Control and Prevention. Available from https://www.cdc.gov/opioids/data-resources/index.html.
   Google Scholar